A Case Report of Behavioral Improvements in a Young Adult with Autism Spectrum Disorder Using Topically Applied Glutathione
Article Sidebar
Main Article Content
Abstract
Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social communication and repetitive behaviors. Emerging evidence suggests oxidative stress and glutathione (GSH) imbalance may contribute to ASD pathophysiology.
Case presentation: We report the case of a 22-year-old male diagnosed with ASD in childhood, presenting with persistent social communication difficulties and anxiety-related behaviors. The patient was administered transdermal glutathione using a cyclodextrin-based nano-carrier beginning in December 2023.
Intervention and outcomes: Behavioral changes were reported within one week of initiation, including reduced anxiety, improved social engagement, and increased daily functioning. A temporary relapse occurred following discontinuation, with improvement upon re-initiation. Observations were primarily based on caregiver reports.
Conclusion: This case suggests a potential association between transdermal glutathione and behavioral changes in ASD. However, due to the observational nature and lack of objective measures, further controlled studies are required.
Article Details
Copyright (c) 2026 Yutani R.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Centers for Disease Control and Prevention (CDC). About Autism Spectrum Disorder [Internet]. 2025 [cited 2025 May 20]. Available from: https://www.cdc.gov/autism Available from: https://www.cdc.gov/autism/about/index.html
Hirota T, King BH. Autism spectrum disorder: a review. JAMA. 2023;329(2):157-168. Available from: https://doi.org/10.1001/jama.2022.23661
Centers for Disease Control and Prevention (CDC). Clinical testing and diagnosis for autism spectrum disorder [Internet]. 2024 [cited 2025 May 20]. Available from: https://www.cdc.gov/autism[
Bjorklund G, Saad K, Chirumbolo S, Kern JK, Geier DA, Geier MR. The impact of glutathione metabolism in autism spectrum disorder. Pharmacol Res. 2021;166:105437. Available from: https://doi.org/10.1016/j.phrs.2021.105437
Frustaci A, Neri M, Cesario A, Adams JB, Domenici E, Dalla Bernardina B, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52(10):2128-2141. Available from: https://doi.org/10.1016/j.freeradbiomed.2012.03.011
Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry. 2012;2:e134. Available from: https://doi.org/10.1038/tp.2012.61
Davinelli S, Medoro A, Siracusano M, Savino R, Saso L, Scapagnini G, et al. Oxidative stress response and NRF2 signaling pathway in autism spectrum disorder. Redox Biol. 2025;83:103661. Available from: https://doi.org/10.1016/j.redox.2025.103661
Aishworiya R, Valica T, Hagerman R. An update on psychopharmacological treatment of autism spectrum disorder. Focus (Am Psychiatr Publ). 2024;22(2):198-211. Available from: https://doi.org/10.1007/s13311-022-01183-1
Santos CLD, Barreto II, Silva ACFD, Soriano JFB, Castro JLS, Tristão LS, et al. Behavioral therapies for the treatment of autism spectrum disorder: a systematic review. Clinics (Sao Paulo). 2025;80:100566. Available from: https://doi.org/10.1016/j.clinsp.2024.100566
Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822. Available from: https://doi.org/10.1126/science.1095833
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010;62(11):1607-1621. Available from: https://doi.org/10.1111/j.2042-7158.2010.01030.x
Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290-314.
Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Nutritional and metabolic status of children with autism vs. neurotypical children. Nutr Metab (Lond). 2011;8:34. Available from: https://doi.org/10.1186/1743-7075-8-34
Frye RE, Melnyk S, Macfabe DF. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl Psychiatry. 2013;3:e220. Available from: https://doi.org/10.1038/tp.2012.143
Ghanizadeh A, Berk M. Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia. Med Gas Res. 2013;3:11. Available from: https://doi.org/10.1186/2045-9912-3-11
Pizzorno J. Glutathione: its role in detoxification and clinical applications. Altern Med Rev. 2014;19(1):1-16. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4684116/
Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. Available from: https://doi.org/10.1007/s00394-014-0706-z
Kern JK, Geier DA, Sykes LK, Haley BE, Geier MR. The relationship between mercury and autism: a comprehensive review and discussion. J Trace Elem Med Biol. 2016;37:8-24. Available from: https://doi.org/10.1016/j.jtemb.2016.06.002